Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
about
Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular DiseaseRelationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing ParathyroidectomyMolecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.NFκB-sensitive Orai1 expression in the regulation of FGF23 release.Predictors of renal function in primary hyperparathyroidism.Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trialFibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional studyFibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional studyFibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.Vitamin d, and kidney disease.Management of hyperphosphataemia in chronic kidney disease-challenges and solutions(1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.Urinary phosphorus excretion per creatinine clearance as a prognostic marker for progression of chronic kidney disease: a retrospective cohort study.Renal phosphate loss in long-term kidney transplantationProteinuria Increases Plasma Phosphate by Altering Its Tubular HandlingPlant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study.Treatment of phosphate retention: The earlier the better?Phosphate Toxicity in CKD: The Killer among UsA comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease.FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study.Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4.Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.FGF-23: the rise of a novel cardiovascular risk marker in CKD.The role of phosphorus in the pathophysiology of chronic kidney disease.Hyperparathyroidism and increased fractional excretion of phosphate predict allograft loss in long-term kidney transplant recipients.Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: a randomized, open-labeled clinical trial.Phosphate Metabolism in CKD Stages 3-5: Dietary and Pharmacological Control.Contribution of calcium, phosphorus and 25-hydroxyvitamin D to the excessive severity of secondary hyperparathyroidism in African-Americans with CKD.Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria.Interaction between phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care.Elevated FGF23 Levels in Mice Lacking the Thiazide-Sensitive NaCl cotransporter (NCC).Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation.TGF-Beta Signaling in Bone with Chronic Kidney Disease
P2860
Q26773120-05F23234-7BC1-4C23-AB42-CDD0DE8CBE92Q27024043-48C7D920-9363-40B3-951D-8EB924B33496Q28546638-82C26124-49FE-4B9B-A7CD-EAEF9FC1E298Q30234751-0A55425B-2E8D-4B52-B150-29F5076D256BQ30315916-D08F3B95-3E0D-4D73-A31D-4C01716335FBQ33568992-83671A3A-A548-4027-A0CF-234359F3FA68Q34320155-22C6F723-A929-4017-B872-47BBD9413E4DQ34557041-FD25EECB-CDB1-4320-B5B4-0A3A92E57666Q34588377-3064D078-6175-40AF-8CE5-4A32B4AD1226Q35099518-C15EA26C-3E6B-45BE-9E3A-31B5AA7B4CDEQ35269754-F16CB339-705A-4A37-A2C4-346D3CAEBE36Q35608435-5F8B4737-9FE5-4B30-A556-73B8B137F441Q35692471-5CFCA543-F53D-4FF8-B608-65405AFD620CQ35717268-1F141432-1730-450F-BC34-1CDA49664473Q35758546-FE3AF1CB-50E8-48F5-B8C4-8686DF96CAAEQ35790525-3926A944-4BD0-4C58-AE9C-D3C17BE945C8Q36059301-F399F4B1-E309-47E4-8E6C-0DE6B980E1FCQ36466010-BB630F0C-4F0A-48E9-9A9B-2944FC9FBD66Q36965142-EB24582F-2686-4E85-B11A-F0F0CEBD241AQ37162734-4AC23DE2-1676-49FB-B792-F0EF16CEDB3BQ37271191-3B3B413A-5F00-4161-A69F-E1BB6958B181Q37284113-30B26D74-763E-4D3E-98D2-5C8B667CE113Q37570164-EF010155-38DC-4E77-9EE5-9C4EF7C17009Q37670438-F96E56F2-37B8-4B5D-B4B8-D926DEB29B63Q37832285-64670DF7-7DC9-4C8B-84FC-686DED31D986Q38031216-8D97685C-0BF4-4B61-A4CB-D04CE5F8199AQ38086910-C5CD5F16-048E-4FDB-8829-C297ED06AB81Q38782222-99445C04-CCA8-4011-B4F2-0843639981E1Q40451914-A939AF50-AA40-470E-AC47-D5030436940CQ41460824-4C1C7636-62D0-4004-9EA5-CF0766BA2E91Q41476606-CFF3CEDD-4489-4C36-A217-00A281AA513EQ42746251-C5D62ECD-9AA9-48ED-923C-7E25DDC27158Q46567135-7983B9D9-C26D-4F0C-9216-CA79C785C7CCQ51301290-8294AEB8-77EE-41BA-839D-7C82D952FBE9Q53597101-5FFE0ECA-E1C2-41DE-B168-355E898175BFQ54306096-0B352031-BFBD-47CC-9283-6E8D50CA5CA3Q55344755-B3EAA142-015B-4EE9-B138-CE68873AFD1CQ55496554-DD4109FF-F5E4-4D20-B462-50E21FCE3B21Q58789309-1D061991-2B25-4710-8F74-7C1AC12FBD74
P2860
Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Fibroblast growth factor-23 in ...... secondary hyperparathyroidism.
@ast
Fibroblast growth factor-23 in ...... secondary hyperparathyroidism.
@en
type
label
Fibroblast growth factor-23 in ...... secondary hyperparathyroidism.
@ast
Fibroblast growth factor-23 in ...... secondary hyperparathyroidism.
@en
prefLabel
Fibroblast growth factor-23 in ...... secondary hyperparathyroidism.
@ast
Fibroblast growth factor-23 in ...... secondary hyperparathyroidism.
@en
P2093
P2860
P356
P1476
Fibroblast growth factor-23 in ...... secondary hyperparathyroidism.
@en
P2093
Bert Bammens
Björn Meijers
Dirk Kuypers
Dirk Vanderschueren
Kathleen Claes
Liesbeth Viaene
Pieter Evenepoel
Yves Vanrenterghem
P2860
P304
P356
10.2215/CJN.08241109
P577
2010-05-06T00:00:00Z